Ireland
--:--IST
Active, not recruiting Observational

A Computational Neuroscience Perspective on the Shared Social Cognitive Deficits of Autism and Schizophrenia

NCT07618767 · tracked via the Priya Life Science Taiwan tracker
Phase
Observational
Started
2025-09-30
Last updated
2026-06-08

Condition(s) studied

SchizophreniaAutism Spectrum Disorder

Study summary

This retrospective cohort study will examine shared neural mechanisms of social cognitive deficits in adults with autism spectrum disorder and adults with schizophrenia using existing clinical, behavioral, and neuroimaging data from National Taiwan University Hospital cohort studies. The study will include adults with autism spectrum disorder, adults with schizophrenia, and healthy control participants.

Resting-state functional magnetic resonance imaging (MRI) and structural MRI data will be analyzed to estimate default mode network functional transition indices. These indices will be compared between diagnostic groups and examined in association with social cognitive and psychiatric symptom measures, including the Social Responsiveness Scale (SRS) and the Positive and Negative Syndrome Scale (PANSS) when applicable. No new participants will be recruited, and no intervention will be administered. The study will use previously collected data from 80 adults with autism spectrum disorder, 79 adults with schizophrenia, and 108 healthy controls.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Previously enrolled in one of the source cohort studies approved by the institutional review board of National Taiwan University Hospital. * Adult participants belonging to one of the following groups: 1. Autism spectrum disorder group: participants with a clinical diagnosis of autism spectrum disorder according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria. 2. Schizophrenia group: participants with a clinical diagnosis of schizophrenia according to DSM-5 criteria. 3. Healthy control group: participants without a history of autism spectrum disorder, schizophrenia, or other major psychiatric or neurodevelopmental disorders according to available source cohort records. * Availability of resting-state functional MRI data acquired under the study MRI protocol. * For participants in the autism spectrum disorder group, availability of autistic trait or social functioning measures, such as the Social Responsiveness Scale, when used in symptom-association analyses. * For participants in the schizophrenia group, availability of psychiatric symptom measures, such as the Positive and Negative Syndrome Scale, when used in symptom-association analyses. Exclusion Criteria: * Missing or incomplete MRI data. * Poor-quality MRI data due to severe artifacts, failed preprocessing, failed registration, or incomplete brain coverage. * Excessive head motion during resting-state fMRI that prevents reliable analysis. * Missing essential demographic or diagnostic information. * Missing required clinical or behavioral measures for specific association analyses. * Healthy controls with documented major psychiatric or neurodevelopmental disorders, if identified in source cohort records.

Primary outcome measure(s)

  • Default Mode Network mean functional state transition velocity, DMNμV — Baseline / retrospective assessment from pre-existing resting-state fMRI data
    DMNμV will be derived from resting-state functional MRI data. Multi-voxel activity patterns within the default mode network will be projected into a two-dimensional state space using multidimensional scaling. The Euclidean distance between consecutive functional states will be calculated, and the mean transition velocity across time points will be used as an index of default mode network functional state stability. Lower DMNμV indicates slower state transition and higher functional state stability.

Trial sites (1)

FacilityCityRegionStatus
National Taiwan University Hospital Taipei Taiwan
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07618767 on ClinicalTrials.gov ↗ ← All trials in Taiwan